
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx has demonstrated notable revenue growth, recording $422K in Q2, an increase from $197K in Q1. The company anticipates strong revenue expansion, projecting revenue levels of $1.3 million in 2025 and $4.5 million in 2026, indicating a positive trajectory in financial performance. The firm's focus on innovative cancer treatment options, supported by its proprietary Trans-Arterial Micro-Perfusion therapy platform, positions it favorably within the biopharmaceutical sector, addressing high unmet medical needs.
Bears say
RenovoRx's financial performance reveals persistent challenges, with a revenue of $0.3 million and a net loss of $2.9 million consistently reported, indicating an inability to generate meaningful revenue amid substantial operational costs. The company’s focus on targeting pancreatic cancer, which has a severely low 5-year survival rate of only 12%, underscores the high-risk nature of its therapeutic goals and market demand. Given these financial metrics and the competitive landscape in cancer therapies, concerns about the company's sustainability and growth potential overshadow any perceived positive elements.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares